

## Curriculum Vitae

|                  |                              |
|------------------|------------------------------|
| Full Name        | Ilaria Barchetta             |
| E-mail           | ilaria.barchetta@uniroma1.it |
| Spoken Languages | Italian, English             |

## Education

| Type  | Year | Institution   | Notes   |
|---|------|---|---|
| University graduation                       | 2007 | Sapienza University<br>Rome, Italy  | Degree in Medicine and Surgery <i>cum laude</i><br><br><b>Title of Thesis: "Relationship between insulin resistance, metabolic syndrome and impaired glucose tolerance. The GENFIEV study"</b>  |
| <b>Post-graduate studies</b>                |      |   |   |
| PhD   | 2011 | Sapienza University<br>Rome, Italy  | PhD in Clinical and Experimental Hepatology<br><br><b>Title of the Project: "Relationship between hypovitaminosis D, metabolic syndrome, type 2 diabetes and NAFLD"</b>   |
| Specialty                                   | 2016 | Sapienza University<br>Rome, Italy  | Degree in Internal Medicine <i>cum laude</i><br><br><b>Title of Thesis: "Adipose tissue inflammation, type 2 diabetes and ectopic fat: role of the adipose tissue dysfunction in intra-parenchymal fat accumulation and systemic inflammation in relation to glucose tolerance"</b> |
| Advanced Professional Training Course (CAF) | 2019 | Sapienza University<br>Rome, Italy  | Degree in "Pedagogy and Medical Teaching"   |
| Training course                             | 2019 | Lipari School on Computational Life Sciences – J.T. Schwartz International School for Scientific Research | Degree in "Computational Metabolomics and Metabolic Diseases"   |
| Training course                             | 2020 | Policlinico Umberto I<br>Sapienza University<br>Rome, Italy   | Good Clinical Practice certification GCP/ICH E6 (R2)  |
| Advanced Professional Training Course (CAF) | 2013 | Sapienza University<br>Rome, Italy  | Degree in "Statistical Methods for Biomedical Practice and Research"  |
| Advanced Professional Training Course       | 2011 | Italian Society of Ultrasonography in Medicine and Biology (SIUMB)  | Degree in "Ultrasonography in Internal Medicine"  |
| Licensure                                   | 2008 | Ordine dei Medici di Roma   | Registration n. 56257   |

## Academic Appointments

| Start   | End     | Institution  | Position   |
|---|---------|--|--|
| May 2022  | ongoing | Department of Experimental Medicine<br>Sapienza University, Rome, Italy                              | <i>Tenure track assistant professor (Rtd-B)</i>  |
| 2017  | 2020    | Department of Experimental Medicine<br>Sapienza University, Rome, Italy                              | <i>Post-doc fellow (Assegnista di Ricerca)</i>   |
| 2016  | 2017    | Department of Internal Medicine and<br>Medical Specialties<br>Sapienza University, Rome, Italy       | <i>Post-doc fellow (Assegnista di Ricerca)</i>   |
| 2015  | 2016    | Diabetes and Endocrinology Unit<br>Department of Clinical Sciences<br>Lund University, Malmö, Sweden | <i>Post-doctoral researcher</i>  |
| <b>National Scientific Qualification for Academic positions</b> |         |  |  |
| 2018  | 2027    | Italian National Agency for the Evaluation of<br>Universities and Research Institutes<br>(ANVUR)     | <i>National Scientific Qualification for<br/>Associate Professor for the SC 06/D2,<br/>SSD MED/13, Endocrinology</i>                         |
| 2021  | 2030    | Italian National Agency for the Evaluation of<br>Universities and Research Institutes<br>(ANVUR)     | <i>National Scientific Qualification for<br/>Associate Professor for the SC 06/B1,<br/>SSD MED/09, Internal Medicine</i>                     |
| 2021  | 2030    | Italian National Agency for the Evaluation of<br>Universities and Research Institutes<br>(ANVUR)     | <i>National Scientific Qualification for<br/>Associate Professor for the SC 06/N1<br/>SSD MED/50, Applied Medical Technical<br/>Sciences</i> |

## Clinical Appointments

| Start    | End      | Institution   | Position  |
|----------|----------|---|---|
| Dec-2020 | Apr-2022 | Azienda Ospedaliero-Universitaria<br>Policlinico Umberto I, Rome, Italy | <i>Dirigente Medico - UOC Medicina Interna<br/>SMIC05-c<br/>DAI Medicina Interna, Scienze Endocrino-<br/>Metaboliche e Malattie Infettive</i>   |
| 2016     | 2020     | Azienda Ospedaliero-Universitaria<br>Policlinico Umberto I, Rome, Italy | <i>Post-doc fellowship with authorization to clinical<br/>activity in wards, day-hospital and outpatient<br/>clinics, Section of Endocrinology and Diabetes,<br/>Sapienza University of Rome. Supervisor: Prof.<br/>Maria Gisella Cavallo</i><br><br><i>Co-investigator and Study Coordinator of clinical<br/>trials in type 1 and type 2 diabetes patients (see<br/>also the specific section below)</i> |
| 2007     | 2011     | Azienda Ospedaliero-Universitaria<br>Policlinico Umberto I, Rome, Italy | <i>Ph.D. with authorization to clinical activity at the<br/>Diabetes outpatient clinics, UOS Centro<br/>Aterosclerosi, Sapienza University. Supervisor:<br/>Prof. Maria Gisella Cavallo</i>   |

## Other Appointments

### Editorial Activity

|                |   |   |
|----------------|---|---|
| 2025 - present | Italian Diabetes Society (SID)                          | <i>Member of the Steering Committee of the SID/SISA Study Group 'Diabetes and Atherosclerosis'"</i>     |
| 2024 – present | Italian Diabetes Society (SID)                          | <i>Secretary of the Steering Committee SID – Lazio Region</i>   |
| 2025 - present | <i>Metabolism and Target Organ Damage</i>               | <i>Guest Editor for the special issue “Leading Metabolic Sciences” Co-Editor with Prof Sonia Najjar</i> |
| 2021 - present | <i>Metabolism and Target Organ Damage</i>               | <i>Member of the Junior Editorial Board</i>   |
| 2020 - present | <i>Nutrition Metabolism and Cardiovascular Disease</i>  | <i>Member of the Editorial Board</i>  |
| 2020 - present | <i>Frontiers in Clinical Diabetes and Healthcare</i>    | <i>Associate Editor for the section “Diabetes Geographic Inequalities”</i>                              |
| 2020 - present | <i>Biomolecules</i>                                     | <i>Member of the Editorial Board</i>  |
| 2020 - 2022    | Italian Diabetes Society (SID)                          | <i>Member of the Editorial Committee</i>  |
| 2018 - present | <i>WikiSID</i> , the online platform on Diabetes of SID | <i>Member of the Steering Committee</i>   |
| 2014 - present | <i>Journal of Endocrinological Investigations</i>       | <i>Member of the Editorial Board</i>  |

## Teaching experience

| Year          | Institution                        | Lecture/Course  |
|---------------|------------------------------------|---|
| 2025          | Sapienza University<br>Rome, Italy | <i>Docente Master in Nutrizione Clinica e Metabolismo<br/>Argomento: “Nuovi orizzonti terapeutici per la cura del diabete”</i>  |
| 2024- ongoing | Sapienza University<br>Rome, Italy | <i>Docente<br/>Facoltà di Medicina e Odontoiatria<br/>Corso di Laurea in Medicina e Chirurgia, C.C.L. D<br/>Insegnamento di Endocrinologia – Patologia Integrata III</i>      |
| 2023 -ongoing | Sapienza University<br>Rome, Italy | <i>Docente<br/>Facoltà di Medicina e Odontoiatria<br/>Corso di Laurea in Medicina e Chirurgia, C.C.L. C<br/>Insegnamento di Medicina Interna e Chirurgia Generale III</i>     |
| 2023 -ongoing | Sapienza University<br>Rome, Italy | <i>Docente<br/>Facoltà di Medicina e Odontoiatria<br/>Corso di Laurea in Medicina e Chirurgia, C.C.L. A<br/>Insegnamento di Metodologia Medico-Scientifica II clinica</i>     |
| 2022/2024     | Sapienza University<br>Rome, Italy | <i>Docente<br/>Facoltà di Medicina e Odontoiatria<br/>Corso di Laurea in Medicina e Chirurgia, C.C.L. A<br/>Insegnamento di Metodologia Medico-Scientifica II pre-clinica</i> |

|               |                                    |   |
|---------------|------------------------------------|---|
| 2021          | Sapienza University<br>Rome, Italy | <i>Docente Master in Nutrizione Clinica e Metabolismo</i><br><i>Argomento: "NAFLD-NASH: inquadramento clinico e diagnostico"</i>  |
| 2020 - 2022   | Sapienza University<br>Rome, Italy | <i>Docente cultore della materia</i><br><i>Facoltà di Medicina e Odontoiatria</i><br><i>Corso di Laurea in Medicina e Chirurgia, C.C.L. A</i><br><i>Insegnamento di Metodologia Medico-Scientifica II</i>   |
| 2017 - 2022   | Sapienza University<br>Rome, Italy | <i>Docente cultore della materia e membro della commissione di esami</i><br><i>Facoltà di Medicina e Odontoiatria</i><br><i>Corso di Laurea in Medicina e Chirurgia, C.C.L. C</i><br><i>Insegnamento di Medicina Interna e Chirurgia Generale III</i> |
| 2013 -ongoing | Sapienza University<br>Rome, Italy | <i>Correlatore di Tesi di Laurea Magistrale per studenti del Corso di Laurea</i><br><i>Magistrale in Medicina e Chirurgia</i>   |

### Society memberships, Awards and Honors

| <b>Year</b> | <b>Institution</b>  | <b>Title</b>  |
|-------------|---|---|
| 2019        | European Association for the study of the Liver (EASL)      | <i>NAFLD Summit, Seville, 2019</i><br><i>Young Researcher Full Grant</i>                    |
| 2018        | Italian Diabetes Society (SID)                              | <i>EASD Meeting, Berlin, 2018</i><br><i>Travel Grant</i>                                    |
| 2018        | European Association for the study of the Liver (EASL)      | <i>NAFLD Summit, Geneve, 2018</i><br><i>Young Researcher Full Grant</i>                     |
| 2018        | European Association for the study of the Liver (EASL)      | <i>EASL "Gut-Liver Axis" Conference, Leuven, 2018</i><br><i>Young Researcher Full Grant</i> |
| 2017        | European Association for the study of the Liver (EASL)      | <i>NAFLD Summit, Rome, 2017</i><br><i>Young Researcher Grant</i>                            |
| 2017        | Italian Diabetes Society (SID)                              | <i>Prize "Umberto Di Mario"</i>   |
| 2016        | Italian Diabetes Society (SID)                              | <i>EASD Meeting, Munich, 2016</i><br><i>Travel Grant</i>                                    |
| 2016        | European Association for the study of the Liver (EASL)      | <i>International Liver Conference, 2016</i><br><i>Award for the Best Poster</i>             |
| 2016        | European Association for the study of the Liver (EASL)      | <i>International Liver Conference, 2016</i><br><i>Young Researcher Full Travel Grant</i>    |
| 2014        | Fondazione DiabeteRicerca<br>Italian Diabetes Society (SID) | <i>1-year Fellowship for conducting a research</i><br><i>project abroad on diabetes</i>     |
| 2014        | Italian Society of Internal Medicine (SIMI)                 | <i>Prize "Alberto Malliani"</i><br><i>Young Investigator Award</i>                          |
| 2013        | DEIduemila  | <i>DEIduemila Prize</i><br><i>Young Researcher in Endocrinology</i>                         |

|            |   |                                    |
|------------|---|------------------------------------|
| 2012       | Parma Diabete - IX Edition; Italian Diabetes Society (SID)                    | <i>Young Investigator Award</i>    |
| 2010       | Clinical School of Hepatology, Course in “Metabolic Liver Diseases”           | <i>Young Researcher Full Grant</i> |
| 2008       | Italian Society of Internal Medicine (SIMI) - Sanofi Aventis Foundation Prize | <i>Young Investigator Award</i>    |
| Since 2010 | Italian Diabetes Society (SID)  | <i>Member</i>                      |
| Since 2011 | European Association for the study of Diabetes (EASD)                         | <i>Member</i>                      |
| Since 2016 | European Association for the study of the Liver (EASL)                        | <i>Member</i>                      |
| Since 2008 | Immunotherapy Diabetes (IMDIAB)   | <i>Member</i>                      |
| Since 2010 | Study group on Atherosclerosis, SID   | <i>Member</i>                      |

### Speaker to International conferences hosted by scientific societies

|            |   |   |
|------------|---|---|
| 30/11/2024 | <i>Invited Lecture -Regional SID - AMD LAZIO Congress, Rome</i>   | <i>“The SUMMER Study”</i>   |
| 25/10/2024 | <i>Oral Presentation 30<sup>th</sup> National SID Congress, Rimini</i>  | <i>“Sitagliptin preserves bone mineralization in women with type 2 diabetes: the SLOWDOWN trial”</i>  |
| 12/09/2024 | <i>Oral Presentation 60th EASD Meeting, Madrid, Spain</i>   | <i>“Efficacy and safety of sitagliptin in preserving bone mineralisation in women with type 2 diabetes: the SLOWDOWN randomised clinical trial”</i> |
| 09/02/2024 | <i>Invited Lecture Conference “Pathophysiology of Sedentarism: How Physical Exercise and Nutrition Counteract Chronic Non-Communicable Diseases”, as part of Sapienza University of Rome's Third Mission Project “Mens Sana in Corpore Activo et Sapiente (MeSiCAS)”, Aula Organi Collegiali – Rectorate, Sapienza University of Rome</i> | <i>“Prevention and treatment of type 2 diabetes through a healthy lifestyle”</i>  |
| 01/12/2023 | <i>Invited Lecture at the conference “Gestational Diabetes: from Diagnosis to Clinical Practice”, Sapienza University of Rome</i>   | <i>“State of the art and new possible scenarios in the treatment of gestational diabetes”</i>   |
| 26/10/2022 | <i>Oral Presentation 29th National SID Congress, Rimini</i>   | <i>“A high FIB-4 predicts impaired bone mineralization in obese individuals with or without type 2 diabetes”</i>                                    |
| 26/10/2022 | <i>Session Moderator 29th National SID Congress, Rimini</i>   | <i>“Predicting the Future”</i>  |
| 19/09/2022 | <i>Oral Presentation titled at the 58th EASD Meeting, Stockholm</i>   | <i>“Increased Fibrosis-4 (Fib-4) score reveals low bone mineralisation in obese individuals with or without type 2 diabetes”</i>                    |
| 10/09/2022 | <i>Invited Lecture Italian Meeting on Endocrinology and Metabolism, Italian Society of Endocrinology, SIE Naples</i>  | <i>“Unmet needs in NAFLD”</i>   |
| 15/09/2022 | <i>ePoster Oral Presentation - EASL International Summit on Non-Alcoholic Fatty Liver Disease – Dublin (Ireland)</i>  | <i>“NAFLD-related liver fibrosis is associated with impaired bone mineralization and degraded micro-architecture in obesity”</i>                    |
| 28/09/2021 | <i>Oral Communication</i>   | <i>“Pro-neurotensin levels and the prediction of</i>  |

|            |   |  |
|------------|---|--|
|            | <i>57th EASD Meeting - Online</i>   | <i>cardiovascular risk in individuals with type 1 diabetes: a longitudinal study with 10-year follow-up</i>  |
| 08/12/2020 | <i>Oral Communication<br/>EGIR (European Group for the Study of Insulin Resistance) &amp; NAFLD EASD Study Group Meeting</i>              | <i>"Reduced biliverdin reductase-A expression in visceral adipose tissue is associated with adipocyte dysfunction and NAFLD in human obesity"</i>  |
| 22/09/2020 | <i>Oral Communication<br/>56th EASD Meeting - Online</i>  | <i>"Relationship between hepatic and systemic angiotensin-like 3, hepatic Vitamin D receptor expression and non-alcoholic fatty liver disease in obesity"</i>                                    |
| 22/09/2020 | <i>Chairperson 56th EASD Meeting</i>  | <i>Poster Section on "Type 2 diabetes treatment IRL"</i>   |
| 14/10/2019 | <i>Invited Lecture<br/>Italian-Swedish Health Summit on Diabetes and Cardiovascular Disease, Karolinska Institute – Stockholm, Sweden</i> | <i>"NAFLD/NASH and chronic vascular complications of type 2 diabetes"</i>  |
| 26/09/2019 | <i>ePoster Oral Presentation - EASL International Summit on Non-Alcoholic Fatty Liver Disease, Sevilla, Spain.</i>                        | <i>"Increased hepatic Angiotensin-Like Protein 3 is associated with NAFLD and with liver expression of vitamin D receptor and vitamin D hydroxylases"</i>  |
| 18/09/2019 | <i>ePoster Oral Presentation<br/>55th EASD Meeting, Barcelona, Spain.</i>   | <i>"Elevated plasma copeptin levels identify non-alcoholic fatty liver disease in obese individuals with and without type 2 diabetes"</i>  |
| 14/03/2019 | <i>Invited Lecture<br/>15th Congress of the Spanish Society of Obesity SEEDO – SEO, Vigo, Spain.</i>                                      | <i>"Neurotensin and Fatty Liver"</i>   |
| 05/10/2018 | <i>Oral Communication<br/>54th EASD Meeting, Berlin, Germany.</i>   | <i>"Elevated plasma proneurotensin levels predict NAFLD and visceral adipose tissue inflammation in adults with and without type 2 diabetes"</i>   |
| 20/09/2018 | <i>ePoster Oral Presentation - EASL International Summit on Non-Alcoholic Fatty Liver Disease, Geneva, Switzerland</i>                    | <i>"Increased liver expression of Vitamin D Receptor is associated with NAFLD, visceral obesity and adipose tissue inflammation"</i>   |
| 08/06/2018 | <i>ePoster Oral Presentation EASL Gut-Liver Axis Monothematic Conference, Leuven Belgium.</i>   | <i>"Increased plasma proneurotensin levels identify NAFLD in adults with and without type 2 diabetes"</i>  |
| 09/11/2017 | <i>ePoster Oral Presentation<br/>EASL International Summit on Non-Alcoholic Fatty Liver Disease, Rome, Italy.</i>                         | <i>"Increased circulating proneurotensin levels identify non-alcoholic fatty liver disease in obese subjects with and without type 2 diabetes"</i>   |
| 14/09/2017 | <i>Oral Communication<br/>53th EASD Meeting, Lisbon, Portugal.</i>  | <i>"Plasma WISP1 is a marker of systemic and adipose tissue inflammation in subjects with type 2 diabetes"</i>   |
| 13/09/2016 | <i>Poster Oral Presentation<br/>52th EASD Meeting, Munich, Germany.</i>   | <i>"Phenotypical heterogeneity linked to adipose tissue dysfunction in patients with type 2 diabetes"</i>  |
| 15/04/2016 | <i>Poster Oral Presentation<br/>International Liver Congress EASL<br/>Barcelona, Spain.</i>   | <i>"Effects of oral high-dose vitamin d supplementation on non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled trial"</i> |
| 03/10/2012 | <i>Poster Oral Presentation<br/>48th EASD Meeting, Berlin, Germany.</i>   | <i>"The association between hypovitaminosis D and metabolic syndrome is not dependent on body fat mass"</i>  |

## Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

| Year | Title  | Program   | Role | Grant Value (Euro) |
|------|--|---|------|--------------------|
| 2024 | “Prediction of cardiovascular diseases in diabetes, the PROVIDE (Prediction and pReventiOn of cardiovascular disease In DiabEtes) study”, EU4Health Programme Project: 101128983.  | ERC - EU4Health Programm  | I    | 524.444            |
| 2023 | “Accelerated aging, multi-dimensional multi-organ senescence, and autoimmunity in chronic metabolic disorders”   | Progetto Ateneo Finanziamenti Medi Sapienza University                            | I    | 10.600             |
| 2022 | "Mens sana in corpore activo": promozione dell'attività fisica per migliorare lo stato di salute, fisica e mentale, e per incentivare la fruizione del patrimonio artistico di Sapienza nelle popolazioni del I e II Municipio ed in particolare in quella con disabilità, negli anziani e nei bambini"        | Finanziamento Terza Missione Sapienza University                                  | I    | 11.000             |
| 2022 | “Neurotensin at the crossroad between impaired gut homeostasis and metabolic disease in humans”  | Progetto Ateneo Finanziamenti Medi Sapienza University                            | PI   | 10.000             |
| 2017 | “A randomized, double blind placebo controlled clinical trial to assess the efficacy and safety of sitagliptin on bone measures in women affected by type 2 diabetes. A gender-oriented approach to address a gender-specific frailty. The SLOWDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) study” | AIFA Finanziamento per la Ricerca Indipendente 2016: <i>Referente Scientifico</i> | I    | 495.000            |
| 2017 | “Interplay between dipeptidyl peptidase-4 and vitamin D in adipose tissue-bone axis in patients with type 2 diabetes”  | Fondazione Eli Lilly “La Ricerca in Italia. Un’idea per il Futuro”                | PI   | 210.000            |
| 2015 | “Valore predittivo di OPN nell’identificare un profilo di rischio cardio-metabolico più severo e malattia cardiovascolare subclinica in pazienti affetti da diabete mellito di tipo 2 senza complicanze micro e macrovascolari del diabete”  | “Avvio alla Ricerca” Sapienza University  | PI   | 2.100              |
| 2014 | “Associazione tra polimorfismo Cdx2 del recettore della vitamina D (VDR) e diabete mellito di tipo 2”  | “Avvio alla Ricerca” Sapienza University  | PI   | 3.900              |
| 2013 | "Studio dell'attività lipoproteinlipasica post-eparinica in portatori della variante 40K del gene ANGPTL4"   | “Avvio alla Ricerca” Sapienza University  | PI   | 3.000              |

## National and International research collaborations

| Period | Group/Project   | Research area            |
|--------|---|--------------------------|
| 2024   | Participation in the MAFLD ICD-11 coding group for the implementation of the 11th edition of the International Classification of Diseases (ICD-11) for metabolic (dysfunction) associated | -Metabolic liver disease |

|            |   |  |
|------------|---|--|
|            | fatty liver disease (MAFLD), Asian Pacific Association for the Study of the Liver.  |  |
| Since 2021 | Darwin Renal Study group<br>Italian Diabetes Society (SID)  | Type 2 diabetes<br>Renal complications   |
| Since 2015 | SUMMER Study Group<br>P.I. Prof. Vincenzo Trischitta  | SUMMER- <i>Sapienza University Mortality and Morbidity Event Rate (SUMMER) study in diabetes</i>   |
| Since 2015 | Prof. Olle Melander,<br>Head of the Division of Hypertension and Cardiovascular Disease<br>Department of Clinical Sciences<br>CRC- Clinical Research Centre, Lund University, Malmö, Sweden | -Role of the gut peptide Neurotensin in metabolic disorders, adipose tissue dysfunction and body fat distribution<br>-Copeptin in metabolic diseases |
| Since 2015 | Prof. Corrado M. Cilio<br>Diabetes and Immunovirology Unit<br>Department of Clinical Sciences<br>CRC- Clinical Research Centre, Lund University, Malmö, Sweden                              | Epigenetic modifications in type 1 diabetes  |
| Since 2008 | IMDIAB Group - Immunotherapies in Diabetes<br>P.I. Prof. Paolo Pozzilli   | Immune intervention therapies at the diagnosis in patients with type 1 diabetes  |
| 2005-2009  | GENFIEV Project<br>Italian Diabete Society (SID)<br>P.I. Prof. Stefano Del Prato  | GENFIEV “ <i>Genetica fisiopatologia ed evoluzione del diabete mellito di tipo 2</i> ”   |

### Partecipation to International Clinical Trials

| Year         | Role                              | Title   |
|--------------|-----------------------------------|---|
| 2023-ongoing | Investigator                      | REIMAGINE 2<br>Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4/2.4 mg and 1.0/1.0 mg once weekly versus semaglutide 2.4 mg and 1.0 mg, cagrilintide 2.4 mg and placebo in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor |
| 2022-2024    | Investigator<br>Study Coordinator | PROXYMO-ADVANCE study D5671C00006<br>A Phase IIb/III Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis with Fibrosis  |
| 2021-2022    | Local Project<br>Coordinator      | Erasmus + Project “Undergraduate Medical University: Module in Nutrition: Connecting health and nutrition to help reducing non-communicable diseases”<br>PROJECT N° 21PCS0003   |
| 2019-2020    | Investigator                      | International, Multicenter, Clinical Trial EU-CAPTURE - <i>A non-interventional cross-sectional study to capture the prevalence of cardiovascular disease in patients with type 2 diabetes in selected Countries in Europe</i>  |
| 2019-2024    | Investigator<br>Study Coordinator | International, Multicenter, Randomised Clinical Trial FLOW - <i>Effetti di semaglutide rispetto al placebo sulla progressione dell'insufficienza renale in soggetti con diabete di tipo 2 e malattia renale cronica</i>   |
| 2018-2020    | Investigator<br>Study Coordinator | International, Multicenter, Clinical Trial INSAX - In-market utilisation of liraglutide used for weight management in Europe: a retrospective medical record review study   |
| 2018-2019    | Investigator                      | International, Multicenter, Clinical Trial SAGE: <i>Multinational, crosssectional, observational study to describe glycemic control and quality of life for type 1 diabetic adult patients.</i>   |
| 2017-2019    | Investigator                      | International, Multicenter Randomised Clinical Trial PRONTO-T1D (I8B-MC-  |



|           |                                   |   |
|-----------|-----------------------------------|---|
|           | Study Coordinator                 | ITRM) - <i>A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes</i>                                      |
| 2016-2018 | Investigator                      | International, Multicenter, Prospective Study REFLECT: <i>Studio prospettico, non interventistico, multicentrico per la valutazione della sicurezza e dell'efficacia di insulina degludec in una popolazione di pazienti con diabete mellito tipo 1 e 2 nella reale pratica clinica</i> |
| 2011-2014 | Investigator<br>Study Coordinator | International, Multicenter, Randomised Clinical Trial Andromeda 1001: <i>A Phase 3, Multinational, Randomized, Double-Blind, Placebo- Controlled, Parallel-Group Study To Investigate The Clinical Efficacy And Safety Of Diapep277® In Newly Diagnosed Type 1 Diabetes Subjects</i>    |
| 2008-2011 | Investigator<br>Study Coordinator | International, Multicenter, Randomised Clinical Trial DEFEND-1: <i>A Phase 3 Trial with Otelixizumab (a humanized anti-CD3 MAb) in type 1 diabetes</i>  |
| 2007-2011 | Investigator<br>Study Coordinator | International, Randomised Clinical Trial - <i>Andromeda 901: double-blind Diapep 277 vs placebo in type 1 diabetes at diagnosis</i>   |

### List of peer-reviewed articles in International journals

1. **Barchetta I**, Zampieri M, Cimini FA, Dule S, Sentinelli F, Passarella G, Oldani A, Karpach K, Bacalini MG, Baroni MG, Reale A, Cavallo MG. Association Between Active DNA Demethylation and Liver Fibrosis in Individuals with Metabolic-Associated Steatotic Liver Disease (MASLD). *Int J Mol Sci.* 2025 Jan 31;26(3):1271. doi: 10.3390/ijms26031271. PMID: 39941038.
2. **Barchetta I**, Dule S, Cimini FA, Sentinelli F, Oldani A, Passarella G, Filardi T, Venditti V, Bleve E, Romagnoli E, Morano S, Lenzi A, Melander O, Baroni MG, Cavallo MG. Circulating Proneurotensin Levels Predict Impaired Bone Mineralisation in Postmenopausal Women With Type 2 Diabetes Mellitus. *Diabetes Metab Res Rev.* 2025 Jan;41(1):e70018. doi: 10.1002/dmrr.70018. PMID: 39655684; PMCID: PMC11629440.
3. Totaro M, **Barchetta I**, Sentinelli F, Cimini FA, Palazzi S, D'Alessandro F, Spagnolo L, Dule S, Barbonetti A, Cavallo MG, Baroni MG. Waist circumference, among metabolic syndrome components, predicts degraded trabecular bone score: a retrospective study of a female population from the 2005-2008 NHANES cohorts. *Front Endocrinol (Lausanne).* 2024 Nov 21;15:1476751. doi: 10.3389/fendo.2024.1476751. PMID: 39640886; PMCID: PMC11617190.
4. Zampieri M, Karpach K, Salerno G, Raguzzini A, **Barchetta I**, Cimini FA, Dule S, De Matteis G, Zardo G, Borro M, Peluso I, Cavallo MG, Reale A. PAR level mediates the link between ROS and inflammatory response in patients with type 2 diabetes mellitus. *Redox Biol.* 2024 Sep;75:103243. doi:10.1016/j.redox.2024.103243. Epub 2024 Jun 18. PMID: 38906011; PMCID:PMC11253151.
5. Zhang H, Targher G, Byrne CD, [...] **MAFLD ICD-11 coding collaborators**. A global survey on the use of the international classification of diseases codes for metabolic dysfunction- associated fatty liver disease. *Hepatol Int.* 2024 Aug;18(4):1178-1201. doi: 10.1007/s12072-024-10702-5. Epub 2024 Jun 15. PMID: 38878111.
6. Lanzillotta C, Tramutola A, Lanzillotta S, Greco V, Pagnotta S, Sanchini C, Di Angelantonio S, Forte E, Rinaldo S, Paone A, Cutruzzola F, Cimini FA, **Barchetta I**, Cavallo MG, Urbani A, Butterfield DA, Di Domenico F, Paul BD, Perluigi M, Duarte JMN, Barone E. Biliverdin Reductase-A integrates

- insulin signaling with mitochondrial metabolism through phosphorylation of GSK3 $\beta$ . *Redox Biol.* 2024 Jul;73:103221. doi: 10.1016/j.redox.2024.103221. Epub 2024 Jun 1. PMID: 38843768; PMCID: PMC11190564.
7. **Barchetta I**, Cavallo MG. Neurotensin: Linking metabolism and cardiovascular disease. *Atherosclerosis.* 2024 May;392:117514. doi: 10.1016/j.atherosclerosis.2024.117514. Epub 2024 Mar 8. PMID: 38503610.
  8. **Barchetta I**, Cimini FA, Sentinelli F, Chiappetta C, Di Cristofano C, Silecchia G, Leonetti F, Baroni MG, Cavallo MG. Reduced Lipopolysaccharide- Binding Protein (LBP) Levels Are Associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Adipose Inflammation in Human Obesity. *Int J Mol Sci.* 2023 Dec 6;24(24):17174. doi: 10.3390/ijms242417174. PMID: 38139003; PMCID: PMC10742626.
  9. Maddaloni E, Carlone A, Pitocco D, Leanza G, Suraci C, Altomare M, Cavallo MG, **Barchetta I**, Morano S, Moretti C, Coraggio L, Visalli N, Tramontana F, Schiaffini R, Crinò A, Buzzetti R, Pozzilli P; IMDIAB study group. Glycated haemoglobin in the first year after diagnosis of type 1 diabetes is an independent risk factor for diabetic retinopathy: The IMDIAB 25 years follow-up study. *Diabetes Obes Metab.* 2023 Nov;25(11):3415-3419. doi: 10.1111/dom.15213. Epub 2023 Jul 14. PMID: 38014612.
  10. Souza M, Diaz I, **Barchetta I**, Mantovani A. Reply to Li and colleagues. *Liver Int.* 2024 Jan;44(1):265. doi: 10.1111/liv.15788. Epub 2023 Nov 13. PMID: 37955391.
  11. Souza M, Diaz I, **Barchetta I**, Mantovani A. Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: A systematic review and meta-analysis. *Liver Int.* 2024 Jan;44(1):6-14. doi: 10.1111/liv.15763. Epub 2023 Oct 13. PMID: 37833849.
  12. **Barchetta I**. Beyond the liver: The role of neurotensin in nonalcoholic fatty liver disease. *J Intern Med.* 2023 Sep;294(3):245-247. doi: 10.1111/joim.13675. Epub 2023 Jun 5. PMID: 37276447.
  13. Cimini FA, Tramutola A, **Barchetta I**, Ceccarelli V, Gangitano E, Lanzillotta S, Lanzillotta C, Cavallo MG, Barone E. Dynamic Changes of BVRA Protein Levels Occur in Response to Insulin: A Pilot Study in Humans. *Int J Mol Sci.* 2023 Apr 14;24(8):7282. doi: 10.3390/ijms24087282. PMID: 37108445; PMCID: PMC10138944.
  14. Dule S, **Barchetta I**, Cimini FA, Passarella G, Dellanno A, Filardi T, Venditti V, Bleve E, Bailetti D, Romagnoli E, Morano S, Baroni MG, Cavallo MG. Reduced High-Density Lipoprotein Cholesterol Is an Independent Determinant of Altered Bone Quality in Women with Type 2 Diabetes. *Int J Mol Sci.* 2023 Mar 30;24(7):6474. doi: 10.3390/ijms24076474. PMID: 37047445; PMCID: PMC10095189.
  15. Sentinelli F, **Barchetta I**, Cimini FA, Dule S, Bailetti D, Cossu E, Barbonetti A, Totaro M, Melander O, Cavallo MG, Baroni MG. Neurotensin Gene rs2234762 C>G Variant Associates with Reduced Circulating Pro-NT Levels and Predicts Lower Insulin Resistance in Overweight/Obese Children. *Int J Mol Sci.* 2023 Mar 30;24(7):6460. doi: 10.3390/ijms24076460. PMID: 37047432; PMCID: PMC10095103.
  16. Maddaloni E, Coraggio L, Amendolara R, Baroni MG, Cavallo MG, Copetti M, Cossu E, D'Angelo P, D'Onofrio L, Cosmo S, Leonetti F, Morano S, Morviducci L, Napoli N, Prudente S, Pugliese G, Park K, Holman RR, Trischitta V, Buzzetti R; **SUMMER Study in Diabetes Group**. Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes. *Diabetes Metab Res Rev.* 2023 Jul;39(5):e3632. doi: 10.1002/dmrr.3632. Epub 2023 Mar 20. PMID: 36880127.

17. Concistrè A, Petramala L, Pugliano CL, Celi M, Vinci F, Assanto E, **Barchetta I**, Perrone EP, Rella S, Iannazzo F, Angheloni A, Coraggio L, Di Rienzo F, Maggi D, Circosta F, Galardo G, Muscaritoli M, Letizia C. Analysis of prognostic factors in COVID-19 hospitalized patients: an Italian single-center case-control study. *Eur Rev Med Pharmacol Sci*. 2023 Feb;27(3):1207-1221. doi: 10.26355/eurrev\_202302\_31232. PMID: 36808370.
18. Morieri ML, Raz I, Consoli A, Rigato M, Lapolla A, Broglio F, Bonora E, Avogaro A, Fadini GP; **DARWIN-FUP network**. Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study. *J Endocrinol Invest*. 2023 Jul;46(7):1429-1439. doi: 10.1007/s40618-022-02002-2. Epub 2023 Jan 9. PMID: 36624223; PMCID: PMC10261249.
19. **Barchetta I**, Lubrano C, Cimini FA, Dule S, Passarella G, Dellanno A, Di Biasio A, Leonetti F, Silecchia G, Lenzi A, Cavallo MG. Liver fibrosis is associated with impaired bone mineralization and microstructure in obese individuals with non-alcoholic fatty liver disease. *Hepatol Int*. 2023 Apr;17(2):357-366. doi: 10.1007/s12072-022-10461-1. Epub 2022 Dec 15. PMID: 36520377.
20. **Barchetta I**, Cimini FA, Dule S, Cavallo MG. Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis. *Biomedicines*. 2022 Sep 16;10(9):2306. doi: 10.3390/biomedicines10092306. PMID: 36140405; PMCID: PMC9496088.
21. Cimini FA, Perluigi M, **Barchetta I**, Cavallo MG, Barone E. Role of Biliverdin Reductase A in the Regulation of Insulin Signaling in Metabolic and Neurodegenerative Diseases: An Update. *Int J Mol Sci*. 2022 May 16;23(10):5574. doi: 10.3390/ijms23105574. PMID: 35628384; PMCID: PMC9141761.
22. Tozzi R, Masi D, Cipriani F, Contini S, Gangitano E, Spoltore ME, **Barchetta I**, Basciani S, Watanabe M, Baldini E, Ulisse S, Lubrano C, Gnassi L, Mariani S. Circulating SIRT1 and Sclerostin Correlates with Bone Status in Young Women with Different Degrees of Adiposity. *Nutrients*. 2022 Feb 25;14(5):983. doi:10.3390/nu14050983. PMID: 35267956; PMCID: PMC8912833.
23. **Barchetta I**, Baroni MG, Melander O, Cavallo MG. New Insights in the Control of Fat Homeostasis: The Role of Neurotensin. *Int J Mol Sci*. 2022 Feb 17;23(4):2209. doi: 10.3390/ijms23042209. PMID: 35216326; PMCID: PMC8876516.
24. Bailetti D, Sentinelli F, Prudente S, Cimini FA, **Barchetta I**, Totaro M, Di Costanzo A, Barbonetti A, Leonetti F, Cavallo MG, Baroni MG. Deep Resequencing of 9 Candidate Genes Identifies a Role for ARAP1 and IGF2BP2 in Modulating Insulin Secretion Adjusted for Insulin Resistance in Obese Southern Europeans. *Int J Mol Sci*. 2022 Jan 22;23(3):1221. doi: 10.3390/ijms23031221. PMID: 35163144; PMCID: PMC8835579.
25. Cimini FA, **Barchetta I**, Bertocchini L, Ceccarelli V, Baroni MG, Melander O, Cavallo MG. High pro-neurotensin levels in individuals with type 1 diabetes associate with the development of cardiovascular risk factors at follow-up. *Acta Diabetol*. 2022 Jan;59(1):49-56. doi: 10.1007/s00592-021-01783-x. Epub 2021 Aug 29. PMID: 34455471; PMCID: PMC8758622.
26. Cimini FA, **Barchetta I**, Zuliani I, Pagnotta S, Bertocchini L, Dule S, Zampieri M, Reale A, Baroni MG, Cavallo MG, Barone E. Biliverdin reductase-A protein levels are reduced in type 2 diabetes and are associated with poor glycometabolic control. *Life Sci*. 2021 Nov 1;284:119913. doi: 10.1016/j.lfs.2021.119913. Epub 2021 Aug 26. PMID: 34453944.
27. Leto G, **Barchetta I**, De Candia L, Magotti MG, Cianciullo M, Manti R, Negri C, Cimino V, Dodesini AR, Zerella F, Baratta R. Identification of the Inappropriate Clinical Actions (DON'T) to Improve the

- Management of Patients with Type 2 Diabetes Failing Basal Insulin Supported Oral Treatment: Results of Survey for a Panel of Diabetes Specialists in Italy. *Diabetes Ther.* 2021 Oct;12(10):2645-2661. doi: 10.1007/s13300-021-01137-4. Epub 2021 Aug 20. PMID: 34415563; PMCID: PMC8478995.
28. **Barchetta I**, Arvastsson J, Sarmiento L, Cilio CM. Epigenetic Changes Induced by Maternal Factors during Fetal Life: Implication for Type 1 Diabetes. *Genes (Basel)*. 2021 Jun 8;12(6):887. doi: 10.3390/genes12060887. PMID: 34201206; PMCID: PMC8227197.
  29. **Barchetta I**, Dule S, Bertocchini L, Cimini FA, Sentinelli F, Bailetti D, Marini G, Barbonetti A, Loche S, Cossu E, Cavallo MG, Baroni MG. The single- point insulin sensitivity estimator (SPISE) index is a strong predictor of abnormal glucose metabolism in overweight/obese children: a long-term follow-up study. *J Endocrinol Invest.* 2022 Jan;45(1):43-51. doi:10.1007/s40618-021-01612-6. Epub 2021 Jun 17. PMID: 34142364; PMCID: PMC8741725.
  30. Zampieri M, Bacalini MG, **Barchetta I**, Scalea S, Cimini FA, Bertocchini L, Tagliatesta S, De Matteis G, Zardo G, Cavallo MG, Reale A. Increased PARylation impacts the DNA methylation process in type 2 diabetes mellitus. *Clin Epigenetics.* 2021 May 17;13(1):114. doi: 10.1186/s13148-021-01099-1. PMID:34001206; PMCID: PMC8130175.
  31. **Barchetta I**, Bertocchini L, Sentinelli F, Bailetti D, Marini G, Cimini FA, Ceccarelli V, Struck J, Schulte J, Loche S, Cossu E, Melander O, Cavallo MG, Baroni MG. Circulating pro-neurotensin levels predict bodyweight gain and metabolic alterations in children. *Nutr Metab Cardiovasc Dis.* 2021 Mar 10;31(3):902-910. doi: 10.1016/j.numecd.2020.11.025. Epub 2020 Dec 5. PMID: 33549442.
  32. Cimini FA, **Barchetta I**, Ceccarelli V, Chiappetta C, Di Biasio A, Bertocchini L, Sentinelli F, Leonetti F, Silecchia G, Di Cristofano C, Baroni MG, Velotti F, Cavallo MG. Granzyme B Expression in Visceral Adipose Tissue Associates With Local Inflammation and Glyco-Metabolic Alterations in Obesity. *Front Immunol.* 2020 Nov 18;11:589188. doi: 10.3389/fimmu.2020.589188. PMID: 33312176; PMCID:PMC7708321.
  33. Velotti F, **Barchetta I**, Cimini FA, Cavallo MG. Granzyme B in Inflammatory Diseases: Apoptosis, Inflammation, Extracellular Matrix Remodeling, Epithelial-to-Mesenchymal Transition and Fibrosis. *Front Immunol.* 2020 Nov 11;11:587581. doi: 10.3389/fimmu.2020.587581. PMID: 33262766; PMCID: PMC7686573.
  34. Ceccarelli V, **Barchetta I**, Cimini FA, Bertocchini L, Chiappetta C, Capoccia D, Carletti R, Di Cristofano C, Silecchia G, Fontana M, Leonetti F, Lenzi A, Baroni MG, Barone E, Cavallo MG. Reduced Biliverdin Reductase-A Expression in Visceral Adipose Tissue is Associated with Adipocyte Dysfunction and NAFLD in Human Obesity. *Int J Mol Sci.* 2020 Nov 29;21(23):9091. doi:10.3390/ijms21239091. PMID: 33260451; PMCID: PMC7730815.
  35. **Barchetta I**, Cimini FA, Cavallo MG. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update. *Nutrients.* 2020 Oct 28;12(11):3302. doi: 10.3390/nu12113302. PMID: 33126575; PMCID: PMC7693133.
  36. **Barchetta I**, Cimini FA, Bertocchini L, Ceccarelli V, Spaccarotella M, Baroni MG, Cavallo MG. Effects of work status changes and perceived stress on glycaemic control in individuals with type 1 diabetes during COVID-19 lockdown in Italy. *Diabetes Res Clin Pract.* 2020 Dec;170:108513. doi:10.1016/j.diabres.2020.108513. Epub 2020 Oct 16. PMID: 33075424; PMCID:PMC7566668.
  37. **Barchetta I**, Chiappetta C, Ceccarelli V, Cimini FA, Bertocchini L, Gaggini M, Cristofano CD, Silecchia G, Lenzi A, Leonetti F, Baroni MG, Gastaldelli A, Cavallo MG. Angiopoietin-Like Protein

- 4 Overexpression in Visceral Adipose Tissue from Obese Subjects with Impaired Glucose Metabolism and Relationship with Lipoprotein Lipase. *Int J Mol Sci.* 2020 Sep 29;21(19):7197. doi: 10.3390/ijms21197197. PMID: 33003532; PMCID: PMC7582588.
38. **Barchetta I**, Ceccarelli V, Cimini FA, Barone E, Sentinelli F, Coluzzi M, Chiappetta C, Bertoccini L, Tramutola A, Labbadia G, Di Cristofano C, Silecchia G, Leonetti F, Cavallo MG. Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease. *J Endocrinol Invest.* 2021 May;44(5):979-988. doi: 10.1007/s40618-020-01392-5. Epub 2020 Aug 27. PMID: 32852705; PMCID: PMC8049937.
39. Sentinelli F, Bertoccini L, Incani M, Pani MG, David F, Bailetti D, Boi A, **Barchetta I**, Cimini FA, Mannino AC, Lenzi A, Cavallo MG, Loche S, Cossu E, Baroni MG. Association of Apelin Levels in Overweight-obese Children with Pubertal Development, but Not with Insulin Sensitivity: 6.5 Years Follow up Evaluation. *Endocr Res.* 2020 Nov;45(4):233-240. doi:10.1080/07435800.2020.1804929. Epub 2020 Aug 13. PMID: 32791927.
40. **Barchetta I**, Cimini FA, Chiappetta C, Bertoccini L, Ceccarelli V, Capoccia D, Gaggini M, Di Cristofano C, Della Rocca C, Silecchia G, Leonetti F, Lenzi A, Gastaldelli A, Cavallo MG. Relationship between hepatic and systemic angiopoietin-like 3, hepatic Vitamin D receptor expression and NAFLD in obesity. *Liver Int.* 2020 Sep;40(9):2139-2147. doi: 10.1111/liv.14554. Epub 2020 Jun 28. PMID: 32510837.
41. Cimini FA, **Barchetta I**, Ciccarelli G, Leonetti F, Silecchia G, Chiappetta C, Di Cristofano C, Capoccia D, Bertoccini L, Ceccarelli V, Carletti R, Fraioli A, Baroni MG, Morini S, Cavallo MG. Adipose tissue remodelling in obese subjects is a determinant of presence and severity of fatty liver disease. *Diabetes Metab Res Rev.* 2021 Jan;37(1):e3358. doi: 10.1002/dmrr.3358. Epub 2020 Jul 1. PMID: 32469428.
42. **Barchetta I**, Cavallo MG, Baroni MG. COVID-19 and diabetes: Is this association driven by the DPP4 receptor? Potential clinical and therapeutic implications. *Diabetes Res Clin Pract.* 2020 May;163:108165. doi:10.1016/j.diabres.2020.108165. Epub 2020 Apr 23. PMID: 32333966; PMCID:PMC7177127.
43. Cimini FA, **Barchetta I**, Carotti S, Morini S, Cavallo MG. Overview of studies of the vitamin D/vitamin D receptor system in the development of non-alcoholic fatty liver disease. *World J Gastrointest Pathophysiol.* 2019 Sep 10;10(2):11-16. doi: 10.4291/wjgp.v10.i2.11. PMID: 31559105; PMCID: PMC6751507.
44. **Barchetta I**, Ciccarelli G, Barone E, Cimini FA, Ceccarelli V, Bertoccini L, Sentinelli F, Tramutola A, Del Ben M, Angelico F, Baroni MG, Lenzi A, Cavallo MG. Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus. *Nutr Metab Cardiovasc Dis.* 2019 Oct;29(10):1087-1094. doi: 10.1016/j.numecd.2019.07.010. Epub 2019 Jul 23. PMID: 31431395.
45. **Barchetta I**, Cimini FA, Ciccarelli G, Baroni MG, Cavallo MG. Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation. *J Endocrinol Invest.* 2019 Nov;42(11):1257-1272. doi:10.1007/s40618-019-01052-3. Epub 2019 May 9. PMID: 31073969.
46. Sarmiento L, Svensson J, **Barchetta I**, Giwerzman A, Cilio CM. Copy number of the X-linked genes TLR7 and CD40L influences innate and adaptive immune responses. *Scand J Immunol.* 2019 Aug;90(2):e12776. doi: 10.1111/sji.12776. Epub 2019 Jun 18. PMID: 31069824.

47. **Barchetta I**, Enhörning S, Cimini FA, Capoccia D, Chiappetta C, Di Cristofano C, Silecchia G, Leonetti F, Melander O, Cavallo MG. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity. *BMC Med.* 2019 Apr 30;17(1):85. doi: 10.1186/s12916-019-1319-4. PMID: 31035998; PMCID: PMC6489227.
48. Cimini FA, Arena A, **Barchetta I**, Tramutola A, Ceccarelli V, Lanzillotta C, Fontana M, Bertocchini L, Leonetti F, Capoccia D, Silecchia G, Di Cristofano C, Chiappetta C, Di Domenico F, Baroni MG, Perluigi M, Cavallo MG, Barone E. Reduced biliverdin reductase-A levels are associated with early alterations of insulin signaling in obesity. *Biochim Biophys Acta Mol Basis Dis.* 2019 Jun 1;1865(6):1490-1501. doi: 10.1016/j.bbadis.2019.02.021. Epub 2019 Feb 28. PMID:30826467.
49. Bailetti D, Bertocchini L, Mancina RM, **Barchetta I**, Capoccia D, Cossu E, Pujia A, Lenzi A, Leonetti F, Cavallo MG, Romeo S, Baroni MG. ANGPTL4 gene E40K variation protects against obesity-associated dyslipidemia in participants with obesity. *Obes Sci Pract.* 2018 Dec 26;5(1):83-90. doi: 10.1002/osp4.311. PMID:30820332; PMCID: PMC6381304.
50. Bertocchini L, Sentinelli F, Incani M, Bailetti D, Cimini FA, **Barchetta I**, Lenzi A, Cavallo MG, Cossu E, Baroni MG. Circulating miRNA-375 levels are increased in autoantibodies-positive first-degree relatives of type 1 diabetes patients. *Acta Diabetol.* 2019 Jun;56(6):707-710. doi: 10.1007/s00592-019-01297-7. Epub 2019 Feb 13. PMID: 30759280.
51. Cimini FA, D'Eliseo D, **Barchetta I**, Bertocchini L, Velotti F, Cavallo MG. Increased circulating granzyme B in type 2 diabetes patients with low-grade systemic inflammation. *Cytokine.* 2019 Mar;115:104-108. doi: 10.1016/j.cyto.2018.11.019. Epub 2018 Nov 22. PMID: 30473178.
52. Bertocchini L, Bailetti D; **SUMMER Study in Diabetes Group**; Buzzetti R, Cavallo MG, Copetti M, Cossu E, D'Angelo P, De Cosmo S, Di Mauro L, Leonetti F, Morano S, Morviducci L, Napoli N, Prudente S, Pugliese G, Trischitta V, Baroni MG. Variability in genes regulating vitamin D metabolism is associated with vitamin D levels in type 2 diabetes. *Oncotarget.* 2018 Oct 9;9(79):34911-34918. doi: 10.18632/oncotarget.26178. PMID: 30405883; PMCID: PMC6201852.
53. **Barchetta I**, Cavallo MG. Technological Support to Intensive Insulin Therapy by a Novel Smartphone Application in Young Adults With Type 1 Diabetes: One Center's Experience. *J Diabetes Sci Technol.* 2019 Jan;13(1):148-149. doi:10.1177/1932296818803937. Epub 2018 Oct 7. PMID: 30295046; PMCID: PMC6313293.
54. **Barchetta I**, Ceccarelli V, Cimini FA, Bertocchini L, Fraioli A, Alessandri C, Lenzi A, Baroni MG, Cavallo MG. Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus. *J Endocrinol Invest.* 2019 May;42(5):513-520. doi: 10.1007/s40618-018-0941-x. Epub 2018 Aug 21. PMID: 30132286.
55. Beveridge LA, Khan F, Struthers AD, Armitage J, **Barchetta I**, Bressendorff I, Cavallo MG, Clarke R, Dalan R, Dreyer G, Gepner AD, Forouhi NG, Harris RA, Hitman GA, Larsen T, Khadgawat R, Marckmann P, Mose FH, Pilz S, Scholze A, Shargorodsky M, Sokol SI, Stricker H, Zoccali C, Witham MD. Effect of Vitamin D. Supplementation on Markers of Vascular Function: A Systematic Review and Individual Participant Meta-Analysis. *J Am Heart Assoc.* 2018 May 30;7(11):e008273. doi: 10.1161/JAHA.117.008273. PMID: 29848497; PMCID:PMC6015391.
56. **Barchetta I**, Cimini FA, Capoccia D, Bertocchini L, Ceccarelli V, Chiappetta C, Leonetti F, Di Cristofano C, Silecchia G, Orho-Melander M, Melander O, Cavallo MG. Neurotensin Is a Lipid-Induced Gastrointestinal Peptide Associated with Visceral Adipose Tissue Inflammation in Obesity. *Nutrients.* 2018 Apr 23;10(4):526. doi: 10.3390/nu10040526. PMID: 29690638; PMCID: PMC5946311.

57. **Barchetta I**, Cimini FA, Leonetti F, Capoccia D, Di Cristofano C, Silecchia G, Orho-Melander M, Melander O, Cavallo MG. Increased Plasma Proneurotensin Levels Identify NAFLD in Adults With and Without Type 2 Diabetes. *J Clin Endocrinol Metab.* 2018 Jun 1;103(6):2253-2260. doi: 10.1210/jc.2017-02751. PMID:29590379.
58. **Barchetta I**, Cimini FA, De Gioannis R, Ciccarelli G, Bertoccini L, Lenzi A, Baroni MG, Cavallo MG. Procollagen-III peptide identifies adipose tissue-associated inflammation in type 2 diabetes with or without nonalcoholic liver disease. *Diabetes Metab Res Rev.* 2018 Jul;34(5):e2998. doi: 10.1002/dmrr.2998. Epub 2018 Mar 24. PMID: 29471595.
59. **Barchetta I**, Ciccarelli G, Cimini FA, Ceccarelli V, Orho-Melander M, Melander O, Cavallo MG. Association between systemic leptin and neurotensin concentration in adult individuals with and without type 2 diabetes mellitus. *J Endocrinol Invest.* 2018 Oct;41(10):1159-1163. doi: 10.1007/s40618-018-0845-9. Epub 2018 Feb 7. PMID: 29417469.
60. Cossu E, Incani M, Pani MG, Gattu G, Serafini C, Strazzera A, Bertoccini L, Cimini FA, **Barchetta I**, Cavallo MG, Baroni MG. Presence of diabetes-specific autoimmunity in women with gestational diabetes mellitus (GDM) predicts impaired glucose regulation at follow-up. *J Endocrinol Invest.* 2018 Sep;41(9):1061-1068. doi: 10.1007/s40618-018-0830-3. Epub 2018 Jan 16. PMID: 29340972.
61. **Barchetta I**, Cimini FA, Capoccia D, De Gioannis R, Porzia A, Mainiero F, Di Martino M, Bertoccini L, De Bernardinis M, Leonetti F, Baroni MG, Lenzi A, Cavallo MG. WISP1 Is a Marker of Systemic and Adipose Tissue Inflammation in Dysmetabolic Subjects With or Without Type 2 Diabetes. *J Endocr Soc.* 2017 Apr 18;1(6):660-670. doi: 10.1210/js.2017-00108. PMID: 29264519; PMCID: PMC5686652.
62. Bertoccini L, Sentinelli F, Incani M, Bailetti D, Cimini FA, **Barchetta I**, Cavallo MG, Cossu E, Lenzi A, Loche S, Baroni MG. The Arg282Ser missense mutation in APOA5 gene determines a reduction of triglyceride and LDL- cholesterol in children, together with low serum levels of apolipoprotein A-V. *Lipids Health Dis.* 2017 Sep 19;16(1):179. doi: 10.1186/s12944-017-0569-4. PMID:28927406; PMCID: PMC5606109.
63. **Barchetta I**, Cimini FA, Cavallo MG. Vitamin D Supplementation and Non-Alcoholic Fatty Liver Disease: Present and Future. *Nutrients.* 2017 Sep 14;9(9):1015. doi: 10.3390/nu9091015. PMID: 28906453; PMCID: PMC5622775.
64. Cimini FA, **Barchetta I**, Porzia A, Mainiero F, Costantino C, Bertoccini L, Ceccarelli V, Morini S, Baroni MG, Lenzi A, Cavallo MG. Circulating IL-8 levels are increased in patients with type 2 diabetes and associated with worse inflammatory and cardiometabolic profile. *Acta Diabetol.* 2017 Oct;54(10):961-967. doi: 10.1007/s00592-017-1039-1. Epub 2017 Aug 23. PMID: 28836077.
65. Cimini FA, **Barchetta I**, Carotti S, Bertoccini L, Baroni MG, Vespasiani-Gentilucci U, Cavallo MG, Morini S. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease. *World J Gastroenterol.* 2017 May 21;23(19):3407-3417. doi:10.3748/wjg.v23.i19.3407. PMID: 28596677; PMCID: PMC5442077.
66. **Barchetta I**, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G, Saulle R, Perri L, Morini S, Tiberti C, Bertoccini L, Cimini FA, Panimolle F, Catalano C, Baroni MG, Cavallo MG. Comment on Elangovan H et al. vitamin D in liver disease: Current evidence and potential directions. *Biochim Biophys Acta* 2017;1863(4):907-916. *Biochim Biophys Acta Mol Basis Dis.* 2017 Sep;1863(9):2388. doi: 10.1016/j.bbadis.2017.04.023. Epub 2017 May 1. PMID: 28473249.

67. Bertoccini L, Sentinelli F, Leonetti F, Bailetti D, Capoccia D, Cimini FA, **Barchetta I**, Incani M, Lenzi A, Cossu E, Cavallo MG, Baroni MG. The vitamin D receptor functional variant rs2228570 (C>T) does not associate with type 2 diabetes mellitus. *Endocr Res.* 2017 Nov;42(4):331-335. doi:10.1080/07435800.2017.1305965. Epub 2017 Apr 7. PMID: 28388281.
68. Sarmiento L, Frisk G, Anagandula M, Hodik M, **Barchetta I**, Netanyah E, Cabrera-Rode E, Cilio CM. Echovirus 6 Infects Human Exocrine and Endocrine Pancreatic Cells and Induces Pro-Inflammatory Innate Immune Response. *Viruses.* 2017 Jan 30;9(2):25. doi: 10.3390/v9020025. PMID: 28146100; PMCID: PMC5332944.
69. **Barchetta I**, Angelico F, Del Ben M, Di Martino M, Cimini FA, Bertoccini L, Polimeni L, Catalano C, Fraioli A, Del Vescovo R, Morini S, Baroni MG, Cavallo MG. Phenotypical heterogeneity linked to adipose tissue dysfunction in patients with Type 2 diabetes. *Clin Sci (Lond).* 2016 Oct 1;130(19):1753-62. doi: 10.1042/CS20160348. Epub 2016 Jul 25. PMID: 27458255.
70. **Barchetta I**, Cimini FA, Bloise D, Cavallo MG. Dipeptidyl peptidase-4 inhibitors and bone metabolism: is vitamin D the link? *Acta Diabetol.* 2016 Oct;53(5):839-44. doi: 10.1007/s00592-016-0882-9. Epub 2016 Jul 5. PMID: 27379733.
71. **Barchetta I**, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G, Saulle R, Perri L, Morini S, Tiberti C, Bertoccini L, Cimini FA, Panimolle F, Catalano C, Baroni MG, Cavallo MG. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. *BMC Med.* 2016 Jun 29;14:92. doi: 10.1186/s12916-016-0638-y. PMID: 27353492; PMCID: PMC4926287.
72. Sentinelli F, Bertoccini L, **Barchetta I**, Capoccia D, Incani M, Pani MG, Loche S, Angelico F, Arca M, Morini S, Manconi E, Lenzi A, Cossu E, Leonetti F, Baroni MG, Cavallo MG. The vitamin D receptor (VDR) gene rs11568820 variant is associated with type 2 diabetes and impaired insulin secretion in Italian adult subjects, and associates with increased cardio-metabolic risk in children. *Nutr Metab Cardiovasc Dis.* 2016 May;26(5):407-13. doi: 10.1016/j.numecd.2016.02.004. Epub 2016 Feb 19. PMID: 27052925.
73. Sentinelli F, Capoccia D, Bertoccini L, **Barchetta I**, Incani M, Coccia F, Manconi E, Lenzi A, Cossu E, Leonetti F, Cavallo MG, Baroni MG. Search for Genetic Variant in the Apelin Gene by Resequencing and Association Study in European Subjects. *Genet Test Mol Biomarkers.* 2016 Feb;20(2):98-102. doi: 10.1089/gtmb.2015.0260. Epub 2016 Jan 20. PMID: 26789934.
74. **Barchetta I**, Capoccia D, Baroni MG, Buzzetti R, Cavallo MG, De Cosmo S, Leonetti F, Leotta S, Morano S, Morviducci L, Prudente S, Pugliese G, Trischitta V; SUMMER Study in Diabetes Group. The "Sapienza University Mortality and Morbidity Event Rate (SUMMER) study in diabetes": Study protocol. *Nutr Metab Cardiovasc Dis.* 2016 Feb;26(2):103-8. doi: 10.1016/j.numecd.2015.09.009. Epub 2015 Oct 9. PMID: 26698225.
75. **Barchetta I**, Alessandri C, Bertoccini L, Cimini FA, Taverniti L, Di Franco M, Fraioli A, Baroni MG, Cavallo MG. Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile. *Eur J Endocrinol.* 2016 Feb;174(2):187-92. doi: 10.1530/EJE-15-0791. Epub 2015 Nov 17. PMID: 26578639.
76. Di Franco M, **Barchetta I**, Iannuccelli C, Gerardi MC, Frisenda S, Ceccarelli F, Valesini G, Cavallo MG. Hypovitaminosis D in recent onset rheumatoid arthritis is predictive of reduced response to treatment and increased disease activity: a 12 month follow-up study. *BMC Musculoskelet Disord.* 2015 Mar 15;16:53. doi: 10.1186/s12891-015-0505-6. PMID: 25887374; PMCID: PMC4373034.



77. **Barchetta I**, Guglielmi C, Bertocchini L, Calella D, Manfrini S, Secchi C, Pozzilli P, Cavallo MG; **IMDIAB** group. Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control. *Acta Diabetol.* 2015 Oct;52(5):873-80. doi: 10.1007/s00592-015-0721-4. Epub 2015 Feb 27. PMID: 25716766.
78. **Barchetta I**, Baroni MG, Leonetti F, De Bernardinis M, Bertocchini L, Fontana M, Mazzei E, Fraioli A, Cavallo MG. TSH levels are associated with vitamin D status and seasonality in an adult population of euthyroid adults. *Clin Exp Med.* 2015 Aug;15(3):389-96. doi: 10.1007/s10238-014-0290-9. Epub 2014 Jun 13. PMID: 24925636.
79. **Barchetta I**, De Bernardinis M, Capoccia D, Baroni MG, Fontana M, Fraioli A, Morini S, Leonetti F, Cavallo MG. Hypovitaminosis D is independently associated with metabolic syndrome in obese patients. *PLoS One.* 2013 Jul 31;8(7):e68689. doi: 10.1371/journal.pone.0068689. PMID: 23935881; PMCID: PMC3729690.
80. Bianchi C, Miccoli R, Trombetta M, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Cavalot F, Cavallo G, Leonetti F, Bonadonna RC, Del Prato S; **GENFIEV Investigators**. Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired  $\beta$ -cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study. *J Clin Endocrinol Metab.* 2013 May;98(5):2100-5. doi: 10.1210/jc.2012-3971. Epub 2013 Mar 28. PMID: 23539736.
81. Napoli N, Strollo R, Pitocco D, Bizzarri C, Maddaloni E, Maggi D, Manfrini S, Schwartz A, Pozzilli P; **IMDIAB Group**. Effect of calcitriol on bone turnover and osteocalcin in recent-onset type 1 diabetes. *PLoS One.* 2013;8(2):e56488. doi: 10.1371/journal.pone.0056488. Epub 2013 Feb 20. PMID: 23437144; PMCID: PMC3577896.
82. Cavallo MG, Sentinelli F, **Barchetta I**, Costantino C, Incani M, Perra L, Capoccia D, Romeo S, Cossu E, Leonetti F, Agati L, Baroni MG. Altered glucose homeostasis is associated with increased serum apelin levels in type 2 diabetes mellitus. *PLoS One.* 2012;7(12):e51236. doi: 10.1371/journal.pone.0051236. Epub 2012 Dec 5. PMID: 23227256; PMCID: PMC3515542.
83. **Barchetta I**. Could vitamin d supplementation benefit patients with chronic liver disease? *Gastroenterol Hepatol (N Y).* 2012 Nov;8(11):755-7. PMID: 24672412; PMCID: PMC3966172.
84. Bianchi C, Miccoli R, Bonadonna RC, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Cavalot F, Cavallo GM, Leonetti F, Del Prato S; **GENFIEV Investigators**. Pathogenetic mechanisms and cardiovascular risk: differences between HbA(1c) and oral glucose tolerance test for the diagnosis of glucose tolerance. *Diabetes Care.* 2012 Dec;35(12):2607-12. doi: 10.2337/dc11-2504. Epub 2012 Aug 21. PMID: 22912427; PMCID: PMC3507559.
85. **Barchetta I**, Carotti S, Labbadia G, Gentilucci UV, Muda AO, Angelico F, Silecchia G, Leonetti F, Fraioli A, Picardi A, Morini S, Cavallo MG. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. *Hepatology.* 2012 Dec;56(6):2180-7. doi: 10.1002/hep.25930. PMID: 22753133.
86. Bizzarri C, Pinto RM, Pitocco D, Astorri E, Cappa M, Hawa M, Giannone G, Palermo A, Maddaloni E, Leslie DR, Pozzilli P; **IMDIAB Group**. Diabetes-related autoantibodies in children with acute lymphoblastic leukemia. *Diabetes Care.* 2012 Mar;35(3):e23. doi: 10.2337/dc11-1946. PMID: 22355026; PMCID: PMC3322684.

87. **Barchetta I**, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, Cavallo MG. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. *BMC Med.* 2011 Jul 12;9:85. doi: 10.1186/1741-7015-9-85. PMID: 21749681; PMCID: PMC3148980.
88. Di Stasio E, Maggi D, Berardesca E, Marulli GC, Bizzarri C, Lauria A, Portuesi R, Cavallo MG, Costantino F, Buzzetti R, Astorri E, Pitocco D, Songini M, Pozzilli P; **IMDIAB Group**. Blue eyes as a risk factor for type 1 diabetes. *Diabetes Metab Res Rev.* 2011 Sep;27(6):609-13. doi: 10.1002/dmrr.1214. PMID: 21557441.
89. **Barchetta I**, Riccieri V, Vasile M, Stefanantoni K, Comberati P, Taverniti L, Cavallo MG. High prevalence of capillary abnormalities in patients with diabetes and association with retinopathy. *Diabet Med.* 2011 Sep;28(9):1039-44. doi: 10.1111/j.1464-5491.2011.03325.x. PMID: 21517956.
90. Bianchi C, Miccoli R, Bonadonna RC, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Alviggi L, Gnasso A, Consoli A, Cavalot F, Cavallo MG, Leonetti F, Giaccari A, Del Prato S; **GENFIEV Investigators**. Metabolic syndrome in subjects at high risk for type 2 diabetes: the genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. *Nutr Metab Cardiovasc Dis.* 2011 Sep;21(9):699-705. doi: 10.1016/j.numecd.2010.03.006. Epub 2010 Nov 5. PMID: 21291660.
91. Bizzarri C, Pitocco D, Napoli N, Di Stasio E, Maggi D, Manfrini S, Suraci C, Cavallo MG, Cappa M, Ghirlanda G, Pozzilli P; **IMDIAB Group**. No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. *Diabetes Care.* 2010 Sep;33(9):1962-3. doi: 10.2337/dc10-0814. PMID: 20805274; PMCID: PMC2928344.
92. Pozzilli P, Strollo R, **Barchetta I**. Natural history and immunopathogenesis of type 1 diabetes. *Endocrinol Nutr.* 2009 Dec;56 Suppl 4:50-2. PMID: 20629233.
93. **Barchetta I**, Sperduti L, Germanò G, Valiante S, Vestri A, Fraioli A, Baroni MG, Cavallo MG. Subclinical vascular alterations in young adults with type 1 diabetes detected by arterial tonometry. *Diabetes Metab Res Rev.* 2009 Nov;25(8):756-61. doi: 10.1002/dmrr.1040. PMID: 19839032.

La sottoscritta, consapevole che – ai sensi dell’art. 76 del D.P.R. 445/2000 – le dichiarazioni mendaci, la falsità negli atti e l’uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali, dichiara che le informazioni riportate rispondono a verità.

La sottoscritta in merito al trattamento dei dati personali esprime il proprio consenso al trattamento degli stessi nel rispetto delle finalità e modalità di cui al d.lgs. n. 196/2003.

Roma, 16/02/2025

Ilaria Barchetta

